Lee, Jong WJong WLeePussegoda, KusalaKusalaPussegodaRassekh, Rod SRod SRassekhMonzon, Jose GJose GMonzonLiu, GeoffreyGeoffreyLiuHwang, SoomiSoomiHwangBhavsar, Amit PAmit PBhavsarPritchard, SheilaSheilaPritchardRoss, Colin JColin JRossCarleton, Bruce CBruce CCarletonAmstutz, UrsulaUrsulaAmstutz2024-10-242024-10-242016-03-05https://boris-portal.unibe.ch/handle/20.500.12422/140823Currently no pharmacogenomics-based criteria exist to guide clinicians in identifying individuals who are at risk of hearing loss from cisplatin-based chemotherapy. This review summarizes findings from pharmacogenomic studies that report genetic polymorphisms associated with cisplatin-induced hearing loss and aims to (1) provide up-to-date information on new developments in the field; (2) provide recommendations for the use of pharmacogenetic testing in the prevention, assessment and management of cisplatin-induced hearing loss in children and adults; and (3) identify knowledge gaps to direct and prioritize future research. These practice recommendations for pharmacogenetic testing in the context of cisplatin-induced hearing loss reflect a review and evaluation of recent literature and are designed to assist clinicians in providing optimal clinical care for patients receiving cisplatin based chemotherapy.en600 - Technology::610 - Medicine & healtharticle10.7892/boris.803492696017010.1097/FTD.0000000000000298